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Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and 
has the highest national COVID-19 death rates per population. The objective of this study is 
to present characteristics and outcomes of patients admitted to medical departments of the 
Hospital of Piacenza during the first wave of the epidemic. 
Methods 
A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were 
included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory 
data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards 
model was fit to assess the association of treatment and other variables with death. 
Results 
Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly 
hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome 
(ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed 
tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 
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(134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive 
care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 
9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, 
having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at 
admission were associated with mortality, while having diarrhea at admission was associated 
with survival. The use of antivirals or corticosteroids was not associated with survival. 
Conclusions 
Overall case fatality rates were high and associated with comorbidities, extensive lung 
involvement, ARDS at admission, and advanced age. The use of antivirals was not associated 
with increased survival. 
 
Abstract word count: 285 
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Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2), detected for the first time in Wuhan, China, in December 2019. 
COVID-19 is thought to have a favorable clinical course in most patients. However, in some 
cases, it may lead to severe pneumonia and eventually to acute respiratory distress syndrome 
(ARDS).[1] To date, there is no established antiviral treatment for COVID-19. Many drugs are 
currently under investigation, while several are being employed in off-label use, and others 
are available via compassionate use or expanded access programs. 
As of October 31st, 2020, 45 667 780 cases of COVID-19 and 1 189 499 deaths have been 
reported worldwide,[2] with 594 472 cases and 37 781 deaths having occurred in Italy.[3] 
Italy, the first Western country reporting sustained COVID-19 transmission, has been 
disproportionately affected by the epidemic.[4–6] In areas of Northern Italy surrounding the 
first COVID-19 cluster in the town of Codogno, public healthcare systems have been 
overwhelmed by the abrupt caseload increase.[7] Limited availability of ventilatory support 
in intensive care units (ICUs) of many hospitals prompted the need to implement forms of 
patient triage. After the first months of the epidemic, the province of Piacenza, the closest to 
the initial cluster, had the highest COVID-19 death rates per population in the country.[8] In 
the Piacenza Hospital, the first proven case was reported on February 21st, 2020.[9] As ICU 
capacity was quickly exhausted by COVID-19 patients, non-ICU medical departments, and in 
particular the Infectious Diseases Unit, had to admit increasing numbers of critically-ill 
patients who needed advanced respiratory support.  
Multiple case series of COVID-19 patients have been published, mostly from China and the 
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common, excluding studies from the ICU setting.[19,20] Moreover, there is a need to 
characterize management and outcomes of severe cases admitted to non-ICU wards. 
In this study, we present the characteristics of patients with severe COVID-19 pneumonia who 
were admitted to four medical departments of the Hospital of Piacenza during the first 
epidemic wave of the outbreak, aiming to describe treatment, case fatality rates, and factors 
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Materials and methods 
Study population and oversight 
Consecutive patients admitted to four non-ICU medical departments (Infectious Diseases, 
Emergency Medicine, and two COVID-19 Units created during the epidemic) of the 
“Guglielmo da Saliceto” Hospital in Piacenza between February 21st, 2020, and May 15th, 
2020, were included in this single-center, retrospective, observational study. Inclusion criteria 
for the study were the following: 1) confirmed COVID-19 cases with positive Sars-CoV-2 
polymerase-chain-reaction (PCR) test, or suspect COVID-19 cases with highly suggestive 
radiologic evidence on chest high-resolution computed tomography (HRCT), in the absence 
of an alternative diagnosis, and 2) severe COVID-19 pneumonia. Children (<18 years old) were 
not included. The study was approved by the local Ethics Committee (Area Vasta Emilia Nord). 
Requirement for informed consent was waived by the Ethics Committee. 
 
Study definitions 
Confirmed and suspect COVID-19 cases, and cases with severe COVID-19 pneumonia were 
defined according to WHO criteria.[21,22] Confirmed COVID-19 cases were defined as 
patients with a positive PCR test for SARS-CoV-2. Suspect COVID-19 cases were defined as 
patients with acute respiratory illness, chest HRCT evidence of lesions compatible with 
COVID-19, and residence in an area reporting community transmission of COVID-19 disease 
during the 14 days prior to symptom onset. Severe COVID-19 pneumonia was defined as 














COVID-19 cases were confirmed using reverse transcriptase real-time PCR on nasopharyngeal 
swab specimen. HRCT scans were routinely performed at hospital admission to diagnose 
pulmonary COVID-19 and to assess the extent of lung involvement. HRCT scans were read by 
expert radiologists, who assessed optically the proportion of lung parenchyma involved by 
viral pneumonia (i.e. interstitial involvement, ground-glass opacities, crazy-paving pattern, 
etc.), as described previously.[23] Blood tests (including blood gas testing) were performed 
at the Clinical Laboratory of the Piacenza Hospital. Results from samples collected on 




Routinely-collected data were retrieved retrospectively from electronic medical files, cross-
checked and collated in an anonymized database. Collected data included demographic and 
clinical characteristics of patients, laboratory and radiologic examinations, treatment and 
oxygen support received, and outcomes. Treatment data were only available for the period 
of hospital stay at the medical departments, but not during the stay in the ICU. Data collection 
was completed and data were locked on June 30th, 2020. 
 
Statistical analysis 
Results of continuous data were reported as median and interquartile range (IQR), while 
categorical data were reported as counts and proportions. Missing data were not imputed. 
Survival analysis was performed to describe the time from hospitalization to death and 
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and by various strata. Tests between strata were done by the log-rank test. The association 
of explanatory variables (patient characteristics, symptoms, comorbidities, laboratory and 
radiologic exams, and treatments) with death was analyzed using a multivariate Cox 
proportional hazards model. Variables were initially included into the multivariate Cox 
proportional hazards model if they predicted the outcome at a p-value ≤ 0.20 in univariate 
analysis and if they fulfilled the proportional hazards assumption; a stepwise backwards 
hierarchical approach was applied for variable selection in the multivariable model.  Hazard 
ratios (HRs) were reported with standard errors and 95%-confidence intervals (CI). No routine 
imputation of missing explanatory variables was done. 
Statistical analysis was performed using Stata software version 15.0 (StataCorp). 
 
Funding 
There is no specific funding to declare for this study. The work of the corresponding author 
(LG) in the Piacenza Hospital was supported by the Italian Society of Infectious and Tropical 














Overall, 245 proven or suspect COVID-19 cases were admitted to the four non-ICU medical 
departments of the Piacenza Hospital during the study period, out of which 218 had severe 
COVID-19 pneumonia and were included in the study. 
 
Demographic and clinical characteristics of the patients 
Baseline clinical characteristics are shown in Table 1. Median age of admitted patients was 68 
years (IQR, 59-76; range, 19-102 years); 172 (79%) patients were male. Median time from first 
symptoms to hospital admission was 7 days (IQR, 5-10 days). Fever (203 patients, 93%), 
dyspnea (159 patients, 73%), and cough (111 patients, 51%) were the most common 
symptoms followed by fatigue (36 patients, 17%) and diarrhea (41 patients, 19%). One 
hundred and fifty patients (69%) had comorbidities with more than half of them (91 patients, 
42%) having more than one known comorbidity. The most common comorbidity was 
hypertension (107 patients, 49%), followed by other cardiovascular diseases (56 patients, 
26%), obesity (52 patients, 24%), and diabetes mellitus (46 patients, 21%). Pulmonary disease 
was reported in 23 patients: chronic obstructive pulmonary disease (COPD) in 17 (8%) and 
bronchial asthma in 6 patients (3%). Other reported comorbidities included chronic kidney 
(20 patients, 9%) and liver (3 patients, 2%) disease, cerebrovascular disease (16 patients, 7%), 
solid cancer (17 patients, 8%), HIV infection (2 patients, 1%), and iatrogenic 
immunosuppression (5 patients, 2%). 
 
Table 1. Baseline clinical characteristics and comorbidities of 218 patients hospitalized with 
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 n (%) 
Demographic characteristics  
Sex, male 172 (79) 
Age, years, median (IQR) [range] 68 (59-76) [19-102] 
Clinical presentation at hospital admission  
Fever 203 (93) 
Dyspnea  159 (73) 
Cough 111 (51) 
Fatigue 36 (17) 
Diarrhea 41 (19) 
Time from symptoms to hospital admission, days, median (IQR) 7 (5-10) 
Comorbidities  
Metabolic disease  
Obesity (BMI>30) 52 (24) 
Diabetes mellitus 46 (21) 
Cardiovascular disease  
Hypertension 107 (49) 
Other cardiovascular disease 56 (26) 
Cerebrovascular disease 16 (7) 
Pulmonary disease  
COPD 17 (8) 
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Solid cancer 17 (8) 
Onco-hematologic cancer 10 (5) 
Chronic kidney disease 20 (9) 
Chronic liver disease 3 (2) 
HIV infection 2 (1) 
Iatrogenic immunosuppression  5 (2) 
Number of comorbidities  
None 68 (31) 
One 59 (27) 
More than one 91 (42) 
Total number, median (IQR) 1 (0-4) 
IQR = interquartile range; BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; HIV = human immunodeficiency virus. 
 
Virology, radiology, and laboratory results on admission  
As shown in Table 2, 216 (99%) patients had a positive PCR for SARS-CoV-2 from a 
nasopharyngeal swab. Two patients tested negative on admission, but had a HRCT scan 
showing bilateral interstitial disease and clinical and epidemiological history which was 
suggestive of COVID-19. The test could not be repeated since these patients died in the first 
day after admission. All 206 patients with available chest HRCT scan performed on hospital 
admission had signs of interstitial lung disease, 201 (98%) of them with bilateral involvement. 
The median proportion of lung parenchyma affected by viral pneumonia was 48% (IQR, 30-
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more of lung parenchyma affected. Twenty-five (12%) patients had pleural effusion. All 
patients had blood oxygen saturation of 93% or less on room air on admission. Arterial blood 
gas analysis found that 33 (15%) patients had an arterial oxygen partial pressure/fractional 
inspired oxygen (PaO2/FiO2) ratio higher than 300 mmHg, 82 patients (38%) had 200-300 
mmHg, 50 patients (23%) had 100-200 mmHg, and 53 patients (24%) had less than 100 mmHg, 
corresponding to no ARDS, mild ARDS, moderate ARDS, and severe ARDS, respectively. 
Results of the baseline blood tests are shown in Table 2. Compared to reference values, 
median values of lymphocyte counts were decreased, while prothrombin time, lactate 
dehydrogenase, ferritin, C-reactive protein, D-dimer, and interleukin-6 were increased. 
 
Table 2. Baseline diagnostic test results of 218 patients hospitalized with severe COVID-19 
pneumonia. 
 n (%) N with available 
results 
Positive PCR for SARS-CoV-2 216 (99) 218 
Respiratory impairment at hospital admission   
Oxygen saturation≤93% 218 (100) 218 
Arterial blood gas test    
PaO2/FiO2≥300 mmHg 33 (15) 218 
PaO2/FiO2≥200 and <300 mmHg 82 (38) 218 
PaO2/FiO2≥100 and <200 mmHg 50 (23) 218 
PaO2/FiO2<100 mmHg 53 (24) 218 
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Any interstitial lung disease 206 (100) 206 
Bilateral lung involvement 201 (98) 206 
Proportion of affected lung parenchyma (visual 




Extended lung involvement (≥50%)  79 (50) 158 
Any pleural effusion 25 (12) 206 
Blood laboratory test, unit (reference range)   
Hematologic   
White blood cells, x103/µl, median (IQR) (4-10) 7.5 (6.0-9.8) 218 
Hemoglobin, g/dl, median (IQR) (13-17) 13.6 (12.2-14.8) 218 
Platelets, x103/µl, median (IQR) (150-450) 197 (157-265) 218 
Lymphocytes, x103/µl, median (IQR) (1,5-4) 0.84 (0.62-1.11) 218 
Biochemistry   
Blood creatinine, mg/dl, median (IQR) (0.6-1.2) 0.99 (0.83-1.25) 218 
Total bilirubin, mg/dl, median (IQR) (0-1.1) 0.67 (0.51-0.90) 206 
Prothrombin time, INR, median (IQR) (0.8-1.1) 1.29 (1.20-1.37) 207 
Partial thromboplastin time, ratio, median 
(IQR) (0.8-1.2) 
0.97 (0.89-1.05) 123 
Lactate dehydrogenase, U/l, median (IQR) (0-
248) 
440 (325-574) 207 
Ferritin, ng/ml, median (IQR) (12-300) 1033 (488-1991) 92 
C-reactive protein, mg/dl, median (IQR) (0-0.5) 13.0 (7.7-18.8) 218 
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D-dimer, ng/ml, median (IQR) (≤500) 1277 (733-4947) 55 
Interleukin-6, pg/ml, median (IQR) (<6.4) 64 (13-205) 40 
PCR = polymerase chain reaction; IQR = interquartile range; HRCT = high resolution computed 
tomography; PaO2 = arterial partial oxygen pressure; FiO2 = fractional inspired oxygen; INR = 
international normalized ratio. 
 
Treatment and respiratory support 
Table 3 summarizes the treatment received by patients. Most patients (187, 86%) received 
antiviral treatment and 169 (78%) received a combination of two or more antivirals. Median 
time from onset of symptoms to the initiation of antiviral treatment was 8 days (IQR, 6-10 
days); median duration of antiviral treatment was 6 days (IQR, 3-9 days). Overall, 181 patients 
(83%) received hydroxychloroquine, 118 patients (54%) received darunavir/cobicistat, 92 
patients (42%) received lopinavir/ritonavir, and 5 patients (2%) received remdesivir. 
Additionally, 134 patients (61%) received corticosteroids. Median time from first symptoms 
to start of corticosteroid treatment was 10 days (IQR, 8-13 days) with a median treatment 
duration of 6 days (IQR, 3-10 days). Azithromycin was used as part of large-spectrum 
antibiotic treatment in 149 patients (68%), and tocilizumab was given to 14 patients (6%). 
Low molecular weight heparin was administered to 172 patients (79%) at a prophylactic dose 
and to 20 patients (9%) at a higher dose. Overall, 60 patients (28%) received ACE inhibitors, 
sartan, or both, for the treatment of hypertension. During hospitalization, all patients were 
administered respiratory support. Table 3 shows the highest level of respiratory support 
which was provided: any among nasal cannula, Venturi mask, or mask with reservoir for 58 
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with continuous positive airway pressure helmets for 88 patients (40%); tracheal intubation 
for 58 patients (27%). Overall, 64 patients (29%) were transferred from the Infectious 
Diseases ward to ICU; median time from hospitalization to ICU admission was 5 days (IQR, 3-
9 days). 
 
Table 3. Treatment, respiratory support received, and outcomes by June 30th, 2020, of 218 
patients hospitalized with severe COVID-19 pneumonia. 
 n (%) 
Treatment*  
Antivirals  
Any antiviral 187 (86) 
Combination of more than one antiviral 169 (78) 
Time from symptoms to antiviral treatment start, days, 
median (IQR) (N=187) 
8 (6-10) 
Antiviral treatment duration, days, median (IQR) (N=187) 6 (3-9) 
Hydroxychloroquine 181 (83) 
Darunavir/cobicistat 118 (54) 
Lopinavir/ritonavir 92 (42) 
Remdesivir 5 (2) 
Corticosteroids  
Any corticosteroid 134 (61) 
Time from symptoms to corticosteroid treatment start, days, 
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Azithromycin 149 (68) 
Tocilizumab 14 (6) 
Low molecular weight heparin, prophylaxis 172 (79) 
Low molecular weight heparin, high dose 20 (9) 
Respiratory support  
Highest level of respiratory support during hospitalization  
Nasal cannula, Venturi mask, mask with reservoir 58 (27) 
High-flow nasal cannula 14 (6) 
CPAP helmet 88 (40) 
Tracheal intubation 58 (27) 
ICU  
Total admitted to ICU 64 (29) 





Total 100 (46) 
At day 28 after hospital admission 93 (43) 
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Discharge from hospital (home or rehabilitation facility)  
Total 109 (50) 
Time from hospital admission to discharge, days, median (IQR) 
(N=109) 
18 (11-27) 
Outcome not assigned  
Total 9 (4) 
Still in ICU at data lock 4 (2) 
Still in hospital at data lock 5 (2) 
IQR = interquartile range; CPAP = continuous positive airway pressure; ICU = intensive care 
unit. 
*This table summarizes treatment received before and during admission at the medical 
departments (i.e. it does not include treatment received in the Intensive Care Unit). 
 
Outcomes 
As of June 30th, 2020, 209 (96%) out of 218 patients had a treatment outcome (Table 3). A 
total of 100 patients (46%) died, 93 (43%) within 28 days after admission to the hospital. 
Overall, 68 (31%) died in the ward and 33 (15%) in ICU. Figure 1 shows Kaplan-Meier curves 
for mortality, overall and stratified by age (log-rank, p<0.0001), extension of lung parenchyma 
affected by pneumonia at chest HRCT scan (log-rank, p<0.0001), and PaO2/FiO2 ratio on 
admission (log-rank, p<0.0001). One hundred-nine patients (50%) were discharged to a 
rehabilitation facility or sent home. Among these patients, median duration of hospitalization 
was 18 days (IQR, 11-27 days). Four patients (2%) were still in ICU and 5 patients (2%) were 
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of patients, stratified across four different groups according to final outcome (death or 
discharge) and to admission to ICU. 
 
 
Figure 1. Mortality of patients with severe COVID-19 pneumonia. 
Kaplan-Meier curves of mortality over 56 days after hospital admission of 218 patients 
hospitalized with severe COVID-19 pneumonia. The figures represent: a) overall mortality, 
with dashed line representing 95% confidence interval and a median time to death of 27 days; 
b) mortality stratified by age (log-rank, p<0.0001); c) mortality stratified by the proportion of 
lung parenchyma affected by interstitial disease at chest computed tomography scan on 
admission (N=158) (log-rank, p=0.0001); d) mortality stratified by P/F ratio on admission (log-
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CT = chest computed tomography; P/F = arterial partial oxygen pressure/fractional inspired 
oxygen. 
 
Figure 2. Time course of patients with severe COVID-19 pneumonia. 
Time course of symptoms, hospital admission, intensive care unit (ICU) admission and 
discharge, initiation and discontinuation of antiviral and corticosteroid therapy, and death or 
discharge of patients hospitalized with severe COVID-19 pneumonia. Patients are divided in 
four groups according to their outcome and to intensive care unit admission: a) patients who 
were not admitted to ICU and were discharged home or to a rehabilitation facility (N=78); b) 
patients who were admitted to ICU and were discharged home or to a rehabilitation facility 
(N=22); c) patients who were admitted to ICU and died (N=67); d) patients who were not 
admitted to ICU and died (N=29). All durations represent median values for each group and 
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ICU = intensive care unit. 
 
Association of treatment and other variables with mortality 
Table 4 shows the results of multivariable Cox proportional-hazards model analysing the 
association of explanatory variables with death. Overall, the following variables were 
independently associated with death: age above 65 years at admission (HR 4.08; 95% CI 2.37-
7.03), more than one comorbidity (HR 1.84; 95% CI 1.04–3.26), severe ARDS at admission (HR 
3.66; 95% CI 1.47–9.07), platelet count <197 x103/µl at admission (HR 2.23; 95% CI 1.42-3.48), 
and LDH >440 U/l at admission (HR 1.98; 95% CI 1.19-3.29). Diarrhea at admission was 
associated with survival (HR 0.31; 0.13–0.72). Of note, antiviral treatment was not associated 
with increased survival, regardless of whether different drugs were entered as individual 
variables (hydroxychloroquine: HR 0.65; 95% CI 0.33–1.30; lopinavir/ritonavir: HR 0.66; 95% 
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(antiviral treatment: HR 0.81; 95% CI 0.43–1.53). Corticosteroid use was associated with 
survival and included in the final model, although the association did not reach statistical 
significance (HR 0.72; 95% CI 0.46–1.14). 
 
Table 4. Association of treatment and other variables with death, assessed using a 






Variables    
Age >65 years at admission 4.08 2.37 – 7.03 <0.001 
Diarrhea at admission 0.31 0.13 – 0.72 0.007 
More than one comorbidity 1.84 1.04 – 3.26 0.036 
Severe ARDS at admission 3.66 1.47 – 9.07 0.005 
Platelet count <197 x103/µl at admission 2.23 1.42 - 3.48 <0.001 
LDH >440 U/l at admission 1.98 1.19 - 3.29 0.008 
Model adjusted by sex, presence of bilateral disease at computed tomography scan, and 
treatment with corticosteroids. 













We hereby report high case fatality rates in patients affected by severe COVID-19 pneumonia 
who were hospitalized in non-ICU wards in Italy, despite the frequent use of antiviral drugs 
and access to non-invasive ventilation support. 
 
In our study, 79% of patients were male, similarly to what has been described for ICU patients 
in Italy.[20] Overall, 85% of patients in our study had ARDS on admission, including 47% with 
moderate or severe ARDS. These rates of ARDS, much higher than in previous studies with a 
similar setting,[10,17,18,24] are more comparable to ICU cohorts,[11,12,16,20,25] and may 
account for the high mortality observed in our study (Figure 1d). The median time from onset 
of symptoms to hospitalization was 7 days, suggesting that our patients developed severe 
illness in a short time. Median age was 68 years, which is higher compared to studies from 
Italy,[20] China,[10,13,15,24,25] Singapore,[26] and the United States,[11,12,14] and to 
surveillance data from Italy.[3] In addition, 69% of patients had at least one comorbidity, 
which is consistent with data from an ICU-based study from Italy,[20] higher than in studies 
from China,[10,13,17,18] although notably lower than in a cohort from the United States.[14] 
As in previous reports, the most common comorbidities were cardiovascular and metabolic 
diseases. Therefore, our observation confirms that older age (Figure 1b) and comorbidities 
are associated with poor outcomes.[16–18,24,27,28] Another relevant finding was that, 
among patients who underwent HRCT on admission, half had 50% or more of lung 
parenchyma affected and 98% had bilateral disease. It has been shown that the score of 
pulmonary involvement is associated with ICU admission/death[23] and the results from our 
study support this conclusion, as well as the routine use of HRCT to assess the extension of 
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had fever, often associated with respiratory symptoms, while gastrointestinal symptoms 
were present in a minority of patients. This is in line with previous reports.[10,12,24,26]  
On admission, most patients had reduced lymphocyte counts and an increase in laboratory 
markers linked to inflammation, such as lactate dehydrogenase, ferritin, C-reactive protein, 
D-dimer, and interleukin-6. These findings are consistent with previous studies indicating the 
decrease of antiviral immune response and the trigger of the cytokine storm.[10,13,14,24,28] 
The vast majority of patients included in the study received at least one antiviral and most of 
them a combination of two, usually hydroxychloroquine and a boosted protease inhibitor 
(lopinavir/ritonavir or darunavir/cobicistat). In addition, 61% of patients were treated with 
corticosteroids. These high rates of treatment were based on local guidelines[29] and 
understandable in light of the clinical severity at presentation. To date, however, the evidence 
backing the efficacy of these drugs is limited. In two randomized controlled trials, 
lopinavir/ritonavir failed to show efficacy compared to standard-of-care.[30,31] The in vivo 
activity of hydroxychloroquine against COVID-19, despite high expectations, has not been 
confirmed in a large randomized, controlled clinical trial.[32] In our study, the use of these 
antivirals, often administered in combination, was not associated with increased survival, 
reinforcing the strong reserves on the efficacy of these drugs for treatment of severe COVID-
19 pneumonia.[33] Corticosteroids are currently a mainstay of treatment of severe COVID-19 
pneumonia: while no benefit had been found in the treatment of other coronaviruses,[34] 
multiple randomized, controlled trials have shown that corticosteroids improve survival rates 
in patients who need oxygen support for COVID-19.[35] More promising agents like 
remdesivir[36] and tocilizumab[37] were prescribed to small numbers of patients and could 
not be assessed in this study. In our study, corticosteroid use was associated with survival, 









Severe COVID-19 pneumonia in Northern Italy 
27 
 
heterogeneous timing of start and duration of treatment with corticosteroids in our cohort, 
and by the small sample size.  
 
The main finding from our study is an overall case fatality rate of 46%, similar to rates reported 
for ICU patients [11,12,16,20,25] and much higher than those reported in studies from non-
ICU wards.[10,13–15,24,26] Mortality rates are often difficult to compare between these two 
groups of studies, also because indications for intensive care and mechanical ventilation may 
change greatly among different settings.[38] Indeed, most of our patients have characteristics 
that would have made them likely eligible for ICU directly at the triage level, had there not 
been a request overload due to the epidemic wave. Most deaths occurred quickly, half in the 
first 7 days of hospitalization and the majority within the first 28 days (Figure 1a). There are 
multiple possible explanations for the high case fatality rate we observed. Above all, the 
characteristics of patients in our study are similar to those of ICU cohorts: high rates of 
comorbidities, extensive lung involvement, high proportion of ARDS at admission, and 
advanced age – all factors associated with mortality. As a matter of fact, during the peak of 
the epidemic in Piacenza Hospital, COVID-19 patients who needed ventilatory support were 
often allocated to non-ICU wards, like the Infectious Diseases or Emergency Medicine Units, 
which acted as a de facto sub-intensive care ward. This study describes the first wave of the 
epidemic, including the peak of COVID-19 admissions, and it is remarkable how non-ICU 
wards were quickly transformed to cope with the emergency, indicating a virtuous learning 
curve. Indeed, a high proportion of patients in our case series died without being admitted to 
the ICU, similarly to what has been reported previously in China,[39] likely reflecting the lack 
of ICU resources. Finally, it has been postulated that high pollution levels in the area may have 













This study has multiple limitations. As described above, the specific epidemic circumstances 
and patient selection must be taken into account. These findings may therefore not be 
representative of the overall characteristics and outcomes of COVID-19 cases in Piacenza and 
of severe COVID-19 pneumonia in general. In addition, 4% of patients were still hospitalized, 
without a final outcome, at data lock. Finally, the retrospective nature of the study explains 
the high rates of missing information for some laboratory tests. 
 
In conclusion, this study describes the features of patients with severe COVID-19 pneumonia, 
their outcomes, and factors associated with mortality. These results warn about the 
consequences of hospital admission of large fluxes of patients that may overwhelm the 
healthcare system, despite swift response and optimal use of available resources. It seems 
therefore paramount to implement adequate prevention policies, while optimizing hospital 
preparedness, and increasing the capacities of medical and ICU wards for the management 
of future pandemic waves. Our results also highlight the dire need for an effective antiviral 
treatment for COVID-19 pneumonia. Hopefully, forthcoming randomized controlled clinical 
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